Nature Biotechnology Contents: Volume 33 pp 567 - 670

If you are unable to see the message below, click here to view.

Advertisement Precision Medicine Excellence EA | Quintiles combines comprehensive genomic technologies with unmatched clinical expertise to help you identify the right pathways, biomarkers and patient populations that will enable you to better predict the long-term safety and efficacy of your products.  TABLE OF CONTENTS June 2015 Volume 33, Issue 6 Editorial News Bioentrepreneur Opinion and Comment Features News and Views Computational Biology Research Careers and Recruitment Advertisement QUINTILES COMPREHENSIVE CANCER PANEL.  A targeted sequencing assay for simultaneous analysis of genomic variation, which may be predictive of response to multiple therapies in clinical development. Identifies pathways, markers of disease and unique variant types to select for patient populations likely to benefit from targeted therapies. Learn More. Japanese table of contents Subscribe   Facebook   RSS   Recommend to library   Twitter   Advertisement BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities   Advertisement Nature Communications is now fully open access All new submissions if accepted, will be published open access and an article processing charge will apply. For more information visit the website.  Visit our open access funding page or contact openaccess@nature.com to learn more on APC funding.   Editorial Top The coming era of human phenotyping   p567 doi:10.1038/nbt.3266 The Apple ResearchKit, the latest effort to bring deep phenotyping to the masses, heralds the arrival of large-scale human population research. News Top First oncolytic virus edges towards approval in surprise vote   pp569 - 570 Cormac Sheridan doi:10.1038/nbt0615-569 CAR-T field booms as next-generation platforms attract big players   pp571 - 572 Chris Morrison doi:10.1038/nbt0615-571 Biogen's anti-LINGO promises nerve repair   p573 doi:10.1038/nbt0615-573b Takeda moves into stem cells   p573 doi:10.1038/nbt0615-573c Heart failure gene therapy disappoints but experts keep the faith   pp573 - 574 Mark Ratner doi:10.1038/nbt0615-573a Industry chases pan-genotypic and shorter HCV treatments   pp575 - 576 Anna Azvolinsky doi:10.1038/nbt0615-575 Cold Spring Harbor in translation   p576 doi:10.1038/nbt0615-576 Alnylam's RNAi therapy targets amyloid disease   p577 Ken Garber doi:10.1038/nbt0615-577a Backlog cripples China's drug regulator   p577 doi:10.1038/nbt0615-577b Brazil approves transgenic eucalyptus   p577 doi:10.1038/nbt0615-577c EC approves long overdue GM plants   p578 doi:10.1038/nbt0615-578b Medtronic deal flurry raises artificial pancreas prospects   pp578 - 579 Emily Waltz doi:10.1038/nbt0615-578a Around the world in a month   p579 doi:10.1038/nbt0615-579 Data Page Drug pipeline: 1Q15   p580 Laura DeFrancesco doi:10.1038/nbt.3261 Bioentrepreneur Top Building a business Bridging tech and biotech   pp581 - 583 Pieter van Rooyen doi:10.1038/nbt.3260 Podcast First Rounders Podcast: Colin Goddard   p583 doi:10.1038/nbt.3255 Opinion and Comment Top Correspondence In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency   pp584 - 586 Azita J Mahiny, Alexander Dewerth, Lauren E Mays, Mohammed Alkhaled, Benedikt Mothes et al. doi:10.1038/nbt.3241 Cardiac regeneration validated   p587 Konstantinos Malliaras and Eduardo Marban doi:10.1038/nbt.3254 Response to Cardiac regeneration validated   p587 Anna V Naumova, Michel Modo, Anna Moore, Joseph A Frank and Charles E Murry doi:10.1038/nbt.3257 Biological products and GAIN Act eligibility   pp588 - 589 Samareh Azeredo da Silveira doi:10.1038/nbt.3253 Accelerating innovation in rapid diagnostics and targeted antibacterials   pp589 - 590 Thomas J Hwang, John H Powers, Daniel Carpenter and Aaron S Kesselheim doi:10.1038/nbt.3251 The ethics of publishing human germline research   pp590 - 592 Arun Sharma and Christopher Thomas Scott doi:10.1038/nbt.3252 Commentary Alexander Rich 1924-2015   pp593 - 598 Shuguang Zhang and Burghardt Wittig doi:10.1038/nbt.3262 One of molecular biology's intellectual leaders, Alex Rich made fundamental discoveries concerning nucleic acids and ribosomes, which served not only as a foundation for modern biology but also spurred the field of biotechnology. Features Top Patents Access to new technologies in multipatented vaccines: challenges for Brazil   pp599 - 603 Cristina Possas, Adelaide Maria de Souza Antunes, Flavia Maria Lins Mendes, Suzanne de Oliveira Rodrigues Schumacher, Reinaldo Menezes Martins et al. doi:10.1038/nbt.3244 Partnerships, technology transfer and targeted policies are needed to accelerate Brazil's participation in global vaccine research and development. Recent patent applications in regenerative medicine   p604 doi:10.1038/nbt.3264 News and Views Top Beyond the reference genome   pp605 - 606 Carlos D Bustamante and Morten Rasmussen doi:10.1038/nbt.3249 Both strands of a diploid genome can now be efficiently sequenced de novo, unlocking the diversity of the human gene pool. See also: Research by Cao et al. Epigenome editing made easy   pp606 - 607 Gabriel E Zentner and Steven Henikoff doi:10.1038/nbt.3248 Fusions of Cas9 to histone-modifying enzymes enable functional interrogation of the epigenome. The heritable immune system   pp608 - 609 Judy Cho doi:10.1038/nbt.3256 Big data sets are galvanizing our ability to decipher the heritability of immune responses. Research Highlights   p609 doi:10.1038/nbt.3250 Biotechnology JOBS of the week Edmond H. Fischer – Washington Research Foundation Endowed Chair in Biochemistry University of Washington (UW) Chair of the McGill University Department of Biochemistry McGill University Research Fellow (Bioinformatics) Singapore Institute for Clinical Sciences (SICS) 3 Positions in Bioinformatics Luxembourg Center for Systems Biomedicine Bioinformatics Specialist Weill Cornell College of Medicine More Science jobs from Biotechnology EVENT 2nd Biotechnology Transfer & Commercialization Conference September 10, 2015 Philadelphia, USA More science events from Computational Biology Top Analysis COMPASS identifies T-cell subsets correlated with clinical outcomes   pp610 - 616 Lin Lin, Greg Finak, Kevin Ushey, Chetan Seshadri, Thomas R Hawn et al. doi:10.1038/nbt.3187 Computational analysis of antigen-specific T cell subsets highlights individual-level variation in immune response quality. Research Top Articles De novo assembly of a haplotype-resolved human genome   pp617 - 622 Hongzhi Cao, Honglong Wu, Ruibang Luo, Shujia Huang, Yuhui Sun et al. doi:10.1038/nbt.3200 A human genome resolved at the haplotype level without a reference genome reveals previously undetected sequences. See also: News and Views by Bustamante & Rasmussen Assembling large genomes with single-molecule sequencing and locality-sensitive hashing   pp623 - 630 Konstantin Berlin, Sergey Koren, Chen-Shan Chin, James P Drake, Jane M Landolin et al. doi:10.1038/nbt.3238 An assembly algorithm that overlaps noisy long reads enables accurate and fast assembly of large genomes from single-molecule real-time sequences. Multiplexed tracking of combinatorial genomic mutations in engineered cell populations   pp631 - 637 Ramsey I Zeitoun, Andrew D Garst, George D Degen, Gur Pines, Thomas J Mansell et al. doi:10.1038/nbt.3177 An approach called TRACE enables mapping of millions of mutations in engineered cell populations. Generation of articular chondrocytes from human pluripotent stem cells   pp638 - 645 April M Craft, Jason S Rockel, Yulia Nartiss, Rita A Kandel, Benjamin A Alman et al. doi:10.10.38/nbt.3210 Articular cartilage cells, which maintain synovial joints, are generated in culture from human pluripotent stem cells. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells   pp646 - 655 Andriana G Kotini, Chan-Jung Chang, Ibrahim Boussaad, Jeffrey J Delrow, Emily K Dolezal et al. doi:10.1038/nbt.3178 Cellular reprogramming is used to pinpoint the genetic abnormalities in a blood cancer caused by a large chromosomal deletion. Letters Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting   pp656 - 660 Huanhuan Joyce Chen, Jian Sun, Zhiliang Huang, Harry Hou Jr, Myra Arcilla et al. doi:10.1038/nbt.3239 New xenograft models of colorectal cancer exhibit metastasis to the liver, use immunocompetent mice and show improved resistance to chemotherapy. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains   pp661 - 667 Junwei Shi, Eric Wang, Joseph P Milazzo, Zihua Wang, Justin B Kinney et al. doi:10.1038/nbt.3235 Cancer drug targets are identified by CRISPR-based screens that knock out functional protein domains. Careers and Recruitment Top Career coaching for scientists   pp668 - 669 Joanne Kamens doi:10.1038/nbt.3259 Looking to make an investment in your future? There are many experienced coaches willing to help. People People   p670 doi:10.1038/nbt.3265 Top Advertisement Celebrating the 25th Anniversary of SELEX: An Aptamer Symposium Supported by the American Society of Gene & Cell Therapy, the Aptamers Workshop will provide a unique opportunity to celebrate the 25th anniversary of aptamers and to meet researchers around the world developing nucleic acid aptamers as high affinity targeting reagents for both diagnosis and therapy. Find out more: www.asgct.org/am15/   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.